The Usefulness of Resistant Maltodextrin and Chitosan Oligosaccharide in Management of Gut Leakage and Microbiota in Chronic Kidney Disease-Reference-Cited by-同舟云学术

The Usefulness of Resistant Maltodextrin and Chitosan Oligosaccharide in Management of Gut Leakage and Microbiota in Chronic Kidney Disease

Published:2023-07-28 Issue:15 Volume:15 Page:3363
ISSN:2072-6643
Container-title:Nutrients
language:en
Short-container-title:Nutrients

Author:

Anegkamol Weerapat¹,Kamkang Panumas¹,Hunthai Sittiphong¹,Kaewwongse Maroot²,Taweevisit Mana³^ORCID,Chuaypen Natthaya¹⁴,Rattanachaisit Pakkapon¹⁵,Dissayabutra Thasinas¹

Affiliation:

1. Metabolic Disease in Gastrointestinal and Urinary System Research Unit, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

2. Division of Physiology, School of Medical Sciences, University of Phayao, Phayao 56000, Thailand

3. Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

4. Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

5. Department of Physiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Abstract

Microbiota-dysbiosis-induced gut leakage is a pathophysiologic change in chronic kidney disease (CKD), leading to the production of several uremic toxins and their absorption into the bloodstream to worsen the renal complications. We evaluate the benefits of resistant maltodextrin (RMD) and chitosan oligosaccharide (COS) supplements in cell culture and CKD-induced rats. The RMD exerted a significant anti-inflammatory effect in vitro and intestinal occludin and zonula occluden-1 up-regulation in CKD rats compared with inulin and COS. While all prebiotics slightly improved gut dysbiosis, RMD remarkably promoted the relative abundance and the combined abundance of Lactobacillus, Bifidobacteria, Akkermansia, and Roseburia in CKD rats. Supplements of RMD should be advantageous in the treatment of gut leakage and microbiota dysbiosis in CKD.

Funder

Rachadapiseksompode Fund

Fundamental Fund

Thailand Research Fund

Program Management Unit for Human Resources and Institutional Development, Research, and Innovation

Publisher

MDPI AG

Subject

Food Science,Nutrition and Dietetics

Link

https://www.mdpi.com/2072-6643/15/15/3363/pdf

Reference53 articles.

1. Voroneanu, L., Burlacu, A., Brinza, C., Covic, A., Balan, G.G., Nistor, I., Popa, C., Hogas, S., and Covic, A. (2023). Gut Microbiota in Chronic Kidney Disease: From Composition to Modulation towards Better Outcomes—A Systematic Review. J. Clin. Med., 12.

2. Rysz, J., Franczyk, B., Ławiński, J., Olszewski, R., Ciałkowska-Rysz, A., and Gluba-Brzózka, A. (2021). The Impact of CKD on Uremic Toxins and Gut Microbiota. Toxins, 13.

3. Lydia, A., Indra, T.A., Rizka, A., and Abdullah, M. (2022). The effects of synbiotics on indoxyl sulphate level, constipation, and quality of life associated with constipation in chronic haemodialysis patients: A randomized controlled trial. BMC Nephrol., 23.

4. Ebrahim, Z., Proost, S., Tito, R.Y., Raes, J., Glorieux, G., Moosa, M.R., and Blaauw, R. (2022). The Effect of ß-Glucan Prebiotic on Kidney Function, Uremic Toxins and Gut Microbiome in Stage 3 to 5 Chronic Kidney Disease (CKD) Predialysis Participants: A Randomized Controlled Trial. Nutrients, 14.

5. A randomized double-blind cross-over trial to study the effects of resistant starch prebiotic in chronic kidney disease (ReSPECKD);Shamloo;Trials,2022